Stock Track | Zenas BioPharma Soars 6.45% in Pre-Market on Positive Phase 3 Trial Results for Obexelimab

Stock Track

05/19

Zenas BioPharma Inc. (ZBIO) shares surged 6.45% in pre-market trading on Tuesday, driven by positive clinical development news for its lead autoimmune disease therapy.

The company announced that detailed results from its pivotal Phase 3 INDIGO trial for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) will be presented at an upcoming medical congress. The trial successfully met its primary endpoint, showing a highly significant 56% reduction in the risk of disease flare compared to placebo over 52 weeks.

Investor sentiment was bolstered by the data, which also indicated that obexelimab met all key secondary efficacy endpoints and demonstrated a favorable safety profile with no new safety signals observed. The announcement provides a significant positive catalyst for the company's late-stage pipeline.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1151355812"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151355812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151355812?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151355812","market":"us","top_or_hot":-1,"title":"Stock Track | Zenas BioPharma Soars 6.45% in Pre-Market on Positive Phase 3 Trial Results for Obexelimab","media":"Stock Track","content":"<p>Zenas BioPharma Inc. (ZBIO) shares surged 6.45% in pre-market trading on Tuesday, driven by positive clinical development news for its lead autoimmune disease therapy.</p><p>The company announced that detailed results from its pivotal Phase 3 INDIGO trial for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) will be presented at an upcoming medical congress. The trial successfully met its primary endpoint, showing a highly significant 56% reduction in the risk of disease flare compared to placebo over 52 weeks.</p><p>Investor sentiment was bolstered by the data, which also indicated that obexelimab met all key secondary efficacy endpoints and demonstrated a favorable safety profile with no new safety signals observed. The announcement provides a significant positive catalyst for the company's late-stage pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zenas BioPharma Soars 6.45% in Pre-Market on Positive Phase 3 Trial Results for Obexelimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zenas BioPharma Soars 6.45% in Pre-Market on Positive Phase 3 Trial Results for Obexelimab\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-19 19:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Zenas BioPharma Inc. (ZBIO) shares surged 6.45% in pre-market trading on Tuesday, driven by positive clinical development news for its lead autoimmune disease therapy.</p><p>The company announced that detailed results from its pivotal Phase 3 INDIGO trial for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) will be presented at an upcoming medical congress. The trial successfully met its primary endpoint, showing a highly significant 56% reduction in the risk of disease flare compared to placebo over 52 weeks.</p><p>Investor sentiment was bolstered by the data, which also indicated that obexelimab met all key secondary efficacy endpoints and demonstrated a favorable safety profile with no new safety signals observed. The announcement provides a significant positive catalyst for the company's late-stage pipeline.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBIO","symbol_name":"Zenas BioPharma Inc.","start_time":0,"source_url":"","article_id":"1151355812","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151355812","pubTimestamp":1779189784,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zenas BioPharma Inc. (ZBIO) shares surged 6.45% in pre-market trading on Tuesday, driven by positive clinical development news for its lead autoimmune disease therapy.The company announced that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBIO":"Zenas BioPharma Inc."},"translate_title":"个股追踪|Obexelimab 3期试验结果积极Zenas BioPharma盘前大涨6.45%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBIO":1},"content_text":"Zenas BioPharma Inc. (ZBIO) shares surged 6.45% in pre-market trading on Tuesday, driven by positive clinical development news for its lead autoimmune disease therapy.The company announced that detailed results from its pivotal Phase 3 INDIGO trial for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) will be presented at an upcoming medical congress. The trial successfully met its primary endpoint, showing a highly significant 56% reduction in the risk of disease flare compared to placebo over 52 weeks.Investor sentiment was bolstered by the data, which also indicated that obexelimab met all key secondary efficacy endpoints and demonstrated a favorable safety profile with no new safety signals observed. The announcement provides a significant positive catalyst for the company's late-stage pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}